Updates are available Correction dated 2025-06-30
Click to view Correction: https://doi.org/10.1038/s41467-025-61430-9
-
Authors
Lv, Xiangmin
Liu, Jiyuan https://orcid.org/0000-0002-0372-4106
Ruan, Jinpeng
Chen, Peichao
He, Chunbo
Zhao, Xingeng
Huang, Cong
Chen, Li
Wang, Hongbo
Hua, Guohua
Shi, Davie https://orcid.org/0009-0003-0498-6321
Yang, Siyi
Moness, Madelyn L.
Montoute, Isabelle
Dhar, Anjali
Chen, Xingcheng
Kumar, Raj
Hu, Lu https://orcid.org/0000-0002-1594-8828
Sadreyev, Ruslan
Yeku, Oladapo https://orcid.org/0000-0002-6319-1647
Wu, Xu
Davis, John S.
Wang, Cheng https://orcid.org/0000-0002-0911-8254
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (2R01CA197976, 1R01CA201500, 1R0CA1238270)
The Colleen’s Dream Foundation (No number) The Ruggles Family Foundation (No number) The Vincent Memorial Hospital Foundation (No number),
- License Information
-
More Information
Article History
Received: 18 April 2023
Accepted: 26 February 2025
First Online: 24 March 2025
Change Date: 30 June 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-61430-9
Competing interests
: Dr. Xu Wu has a financial interest in Tasca Therapeutics, which is developing small molecule modulators of TEAD palmitoylation and transcription factors. Dr. Wu’s interests were reviewed and are managed by Mass General Hospital, and Mass General Brigham in accordance with their conflict-of-interest policies. The rest authors have no competing interests to declare.
